| scholarly article | Q13442814 |
| P50 | author | JoAnn E. Manson | Q6204013 |
| Jean Wactawski-Wende | Q30001860 | ||
| Karen L. Margolis | Q67453328 | ||
| Thomas Rohan | Q87760016 | ||
| Howard D Strickler | Q89146137 | ||
| Rowan T Chlebowski | Q89795128 | ||
| Anne McTiernan | Q91493819 | ||
| Marc J Gunter | Q99408783 | ||
| Aaron K Aragaki | Q114328116 | ||
| Mara Z Vitolins | Q61319157 | ||
| P2093 | author name string | David M Euhus | |
| Robert Wallace | |||
| Lawrence S Phillips | |||
| Virginia G Kaklamani | |||
| Eli Ipp | |||
| P2860 | cites work | Diabetes and cancer: a consensus report. | Q27686977 |
| Metformin induces unique biological and molecular responses in triple negative breast cancer cells | Q28244833 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| Identifying persons with diabetes using Medicare claims data | Q31443172 | ||
| Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. | Q33718914 | ||
| Metformin: a therapeutic opportunity in breast cancer | Q33733319 | ||
| Long-term metformin use is associated with decreased risk of breast cancer. | Q33873130 | ||
| Medical comorbidities predict mortality in women with a history of early stage breast cancer | Q33956785 | ||
| Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. | Q34182185 | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Q34609508 | ||
| The delivery of preventive services in primary care practices according to chronic disease status | Q73550422 | ||
| Health promotion and early detection of cancer in older adults: needs assessment for program development | Q73965186 | ||
| Screening mammogram utilization in women with diabetes | Q77292252 | ||
| Outcomes ascertainment and adjudication methods in the women's health initiative | Q79202519 | ||
| Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer | Q80285083 | ||
| Diabetes mellitus and risk of breast cancer: a meta-analysis | Q34614029 | ||
| Associations of insulin resistance and adiponectin with mortality in women with breast cancer | Q34662835 | ||
| Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. | Q34662845 | ||
| Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study | Q34662854 | ||
| Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer | Q34662865 | ||
| Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes | Q34862358 | ||
| Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer | Q34984314 | ||
| Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer | Q35511314 | ||
| Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women | Q35563646 | ||
| Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study | Q35620231 | ||
| Diabetes mellitus and breast cancer | Q36026132 | ||
| Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. | Q36070998 | ||
| Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis | Q36710824 | ||
| Estrogen plus progestin therapy and breast cancer in recently postmenopausal women | Q37163009 | ||
| Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer | Q37171293 | ||
| Prevalence and predictors of breast and cervical cancer screening among Spanish women with diabetes | Q37269514 | ||
| New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes | Q37319178 | ||
| Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements | Q37375850 | ||
| Regional variations in cancer screening rates found in women with diabetes | Q37654191 | ||
| Ki67 in breast cancer: prognostic and predictive potential | Q37691691 | ||
| Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents | Q37803154 | ||
| Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group | Q39513392 | ||
| Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro | Q39883174 | ||
| Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells | Q40216291 | ||
| A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias | Q40241068 | ||
| Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study | Q44453199 | ||
| Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark | Q44608163 | ||
| More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin | Q44815426 | ||
| Comorbidity as a predictor of stage of illness for patients with breast cancer | Q45269985 | ||
| Cancer occurrence in Danish diabetic patients: duration and insulin effects | Q45387850 | ||
| Metformin, diet and breast cancer: an avenue for chemoprevention. | Q45942865 | ||
| Insulin-lowering effects of metformin in women with early breast cancer | Q46202863 | ||
| Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. | Q51545574 | ||
| Statistics in medicine--reporting of subgroup analyses in clinical trials. | Q51899945 | ||
| Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. | Q53086583 | ||
| Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. | Q54570063 | ||
| Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. | Q54583667 | ||
| Implementation of the women's health initiative study design | Q57055364 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| breast cancer | Q128581 | ||
| P304 | page(s) | 2844-2852 | |
| P577 | publication date | 2012-06-11 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Diabetes, metformin, and breast cancer in postmenopausal women | |
| P478 | volume | 30 |
| Q92342082 | A systematic flux analysis approach to identify metabolic vulnerabilities in human breast cancer cell lines |
| Q34042627 | AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. |
| Q27331637 | Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment |
| Q42561379 | Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer |
| Q35186057 | Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index |
| Q36145731 | Association between Metformin Therapy and Breast Cancer Incidence and Mortality: Evidence from a Meta-Analysis |
| Q37193432 | Association between metformin therapy and mortality after breast cancer: a population-based study |
| Q65001909 | Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. |
| Q36568614 | Association of diabetes and diabetes treatment with incidence of breast cancer |
| Q33714257 | Associations among Metabolism, Circadian Rhythm and Age-Associated Diseases |
| Q35850213 | Associations between diabetes medication use and risk of second breast cancer events and mortality |
| Q38147841 | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates |
| Q26774580 | Biomarkers of cancer angioprevention for clinical studies |
| Q44462595 | Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis |
| Q33646525 | CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis |
| Q58802069 | Chinese herbal products and the reduction of risk of breast cancer among females with type 2 diabetes in Taiwan: A case-control study |
| Q45093278 | Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes |
| Q38976502 | Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women |
| Q92308375 | Comparative Study of Crude and Wine-Processing Corni Fructus on Chemical Composition and Antidiabetic Effects |
| Q37228939 | Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study |
| Q47637594 | Conjugated fatty acid-rich oil from Gynostrmma pentaphyllum seed can ameliorate lipid and glucose metabolism in type 2 diabetes mellitus mice |
| Q33599463 | Current strategies for the prevention of breast cancer |
| Q44459340 | Demographic and clinico-pathological characteristics in patients with invasive breast cancer receiving metformin. |
| Q38097984 | Diabetes and cancer relationships |
| Q92866208 | Diabetes and differences in detection of incident invasive breast cancer |
| Q35373602 | Diabetes, diabetes treatment and breast cancer prognosis |
| Q36794283 | Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative |
| Q40261005 | Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea. |
| Q37228018 | Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients |
| Q37247194 | Effects of sulfonylureas on tumor growth: a review of the literature |
| Q37422431 | Evaluation of Diabetic Patients with Breast Cancer Treated with Metformin during Adjuvant Radiotherapy |
| Q85217506 | FASNating targets of metformin in breast cancer stem-like cells |
| Q38244345 | Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin |
| Q98384744 | Glucose 6-phosphate dehydrogenase inhibition sensitizes melanoma cells to metformin treatment |
| Q61800276 | High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells |
| Q35163721 | Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models |
| Q35046074 | Metformin and breast and gynecological cancer risk among women with diabetes |
| Q33611185 | Metformin and breast cancer stage at diagnosis: a population-based study |
| Q34135248 | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders |
| Q26472029 | Metformin for endometrial hyperplasia |
| Q47404052 | Metformin for endometrial hyperplasia. |
| Q36105494 | Metformin for endometrial hyperplasia: a Cochrane protocol |
| Q34357983 | Metformin in cancer prevention and therapy |
| Q36801172 | Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. |
| Q38973866 | Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using human lymphoblastoid cell lines |
| Q92993152 | Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population-based cohort study |
| Q36729549 | Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma |
| Q26850912 | Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review |
| Q37523998 | Metformin use and endometrial cancer survival |
| Q36062114 | Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b |
| Q37608817 | Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention |
| Q91962344 | Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer |
| Q33773047 | Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival |
| Q30361298 | Obesity and cancer pathogenesis. |
| Q37690552 | Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression |
| Q36711193 | Obesity, diabetes mellitus, and the risk of female breast cancer in Eastern China. |
| Q90387216 | Phase 1 Study of Erlotinib and Metformin in Metastatic Triple-Negative Breast Cancer |
| Q38097730 | Postmenopausal breast cancer, androgens, and aromatase inhibitors. |
| Q33688699 | Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies |
| Q41083568 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? |
| Q38203354 | Recent and current Phase II clinical trials in endometrial cancer: review of the state of art. |
| Q35145204 | Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma |
| Q92507283 | Relationship between Diabetes and Diabetes Medications and Risk of Different Molecular Subtypes of Breast Cancer |
| Q91646021 | Relevance of Translation Initiation in Diffuse Glioma Biology and its Therapeutic Potential |
| Q40600342 | Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes. |
| Q34998410 | Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer |
| Q34413441 | Roles of tumor suppressors in regulating tumor-associated inflammation |
| Q38222468 | Studying cancer treatment in the elderly patient population |
| Q41241629 | The association between glucose-lowering drug use and mortality among breast cancer patients with type 2 diabetes. |
| Q35000522 | The effect of metformin on breast cancer outcomes in patients with type 2 diabetes |
| Q37288186 | The impact of comorbidity on cancer survival: a review |
| Q46776885 | The impact of diabetes mellitus on breast cancer outcomes: a single center retrospective study |
| Q33660253 | The quality control theory of aging |
| Q35782187 | Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress |
| Q34995690 | Type 2 diabetes and mammographic breast density among underserved women |
| Q36582700 | Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk |
| Q46919408 | Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women |
| Q38222517 | Update on prognostic markers for endometrial cancer |
| Q64899623 | Virtual screening of novel compounds as potential ER-alpha inhibitors. |
| Q30572730 | Weight gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? |
Search more.